Biocept's average Accounts Payable for the
three
months ended in Jun. 2023 was $1.50 Mil. Biocept's Cost of Goods Sold for the
three
months ended in Jun. 2023 was $2.55 Mil.
Hence, Biocept's Days Payable for the
three
months ended in Jun. 2023 was 53.68.
The historical rank and industry rank for Biocept's Days Payable or its related term are showing as below:
BIOCQ's Days Payable is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 65.385 * Ranked among companies with meaningful Days Payable only.
Biocept's Days Payable
declined
from Jun. 2022 (73.39) to Jun. 2023 (53.68).
It may suggest that Bioceptaccelerated paying its suppliers.
Biocept Days Payable Related Terms
Biocept Days Payable Historical Data
* Premium members only.
The historical data trend for Biocept's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOCQ vs IDTA, DIGP, ABMC: Days Payable Comparison
For the Diagnostics & Research subindustry, Biocept's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocept Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Days Payable distribution charts can be found below:
* The bar in red indicates where Biocept's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Biocept's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocept (BIOCQ) has a Days Payable of 53.68 as of Jun. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biocept and its competitors.
Is Biocept's Days Payable too high?
Biocept's current Days Payable is 53.68. The Medical Diagnostics & Research industry median Days Payable is 65.39. Biocept's value of 53.68 is 17.9% below this industry median. Overall, Biocept has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biocept's Days Payable compare to IDTA and DIGP?
Biocept's Days Payable of 53.68 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Days Payable is 65.39. Biocept's value of 53.68 is 17.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.39, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocept's current Days Payable of 53.68 is 17.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biocept and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocept's current Days Payable is 53.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocept stock overvalued right now?
Biocept (BIOCQ) has a current Days Payable of 53.68. The current Days Payable is 53.68 and 17.9% below the Medical Diagnostics & Research industry median of 65.39. Biocept's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biocept (BIOCQ), the current Days Payable is 53.68 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
16GF Score
Get the complete analysis for BIOCQ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOCQ has been successfully added to your 
